IP Library Granted Patent US 11,939,373
Granted Patent B2
US 11,939,373 · App. 17/022,465 · Granted Mar 26, 2024

Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit

Inventor: Martin Phillips (Bryn Mawr, PA)
Assignee: OPSIDIO, LLC
C07K16/24A61P11/00A61P11/06A61P29/00A61P37/08C12N15/63A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/76C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,939,373
App. No.
17/022,465
Granted
Mar 26, 2024
Kind
B2
Abstract

The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders.

Claims (29)

1. An antibody that specifically binds to stem cell factor (SCF), wherein the antibody comprises a heavy chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 1, 2, and 3, respectively; and a light chain CDR1, CDR2, and CDR3 comprising SEQ ID NOs: 4, 5, and 6, respectively.

2. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable region amino acid sequence selected from SEQ ID NOs: 7, 8, 9, 10, and 11; and a light chain variable region amino acid sequence selected from SEQ ID NOs: 13, 14, 15, and 16.

3. The antibody of claim 1 , wherein the antibody comprises:

(a) a heavy chain variable region amino acid sequence according to SEQ ID NO: 7 and a light chain variable region amino acid sequence according to SEQ ID NO: 16;

(b) a heavy chain variable region amino acid sequence according to SEQ ID NO: 8 and a light chain variable region amino acid sequence according to SEQ ID NO: 16;

(c) a heavy chain variable region amino acid sequence according to SEQ ID NO: 9 and a light chain variable region amino acid sequence according to SEQ ID NO: 16;

(d) a heavy chain variable region amino acid sequence according to SEQ ID NO: 10 and a light chain variable region amino acid sequence according to SEQ ID NO: 16; or

(e) a heavy chain variable region amino acid sequence according to SEQ ID NO: 11 and a light chain variable region amino acid sequence according to SEQ ID NO: 16.

4. The antibody or fragment thereof of claim 1 , comprising:

(i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 8; and

(ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 16.

5. The antibody of claim 1 , wherein the antibody is humanized.

6. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

7. The antibody of claim 6 , wherein the antibody comprises a human IgG4 domain.

8. The antibody of claim 7 , wherein the IgG4 domain comprises a S241P mutation at amino acid residue 241 and an L248E mutation at amino acid residue 248, wherein the numbering of the residues is that of the Kabat numbering system.

9. The antibody of claim 7 , wherein the human IgG4 domain comprises the amino acid sequence of SEQ ID NO: 40.

10. The antibody of claim 6 , wherein the antibody comprises a heavy chain according to SEQ ID NO: 42 and a light chain according to SEQ ID NO: 49; or wherein the antibody comprises a heavy chain according to SEQ ID NO: 43 and a light chain according to SEQ ID NO: 49.

11. The antibody of claim 1 , wherein

(a) the antibody blocks the interaction between SCF and c-Kit;

(b) the antibody causes internalization of SCF; and/or

(c) the antibody specifically binds to SCF248 and does not bind to SCF220.

12. The antibody of claim 1 , wherein the antibody binds to an epitope comprising at least 8 contiguous amino acids of SEQ ID NO: 33, wherein the antibody inhibits the interaction of SCF248 with c-Kit.

13. The antibody or fragment thcrcof of claim 12 , wherein the epitope consists of SEQ ID NO: 33.

14. The antibody or fragment thereof of claim 1 , comprising: a light chain human Ig kappa constant domain.

15. The antibody of claim 14 , wherein the light chain human Ig kappa constant domain comprises the amino acid sequence of SEQ ID NO: 41 .

16. The antibody of claim 1 , comprising: a light chain human Ig lambda constant domain.

17. An anti-stem cell factor (SCF) antibody that specifically binds to SCF, comprising:

(i) a heavy chain, wherein each heavy chain comprises the amino acid sequence of SEQ ID NO: 42; and

(ii) a light chain, wherein each light chain comprises the amino acid sequence of SEQ ID NO: 49.

Assignments (4)
PATENT SECURITY AGREEMENT (2L) Recorded Apr 6, 2026
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS PURCHASER
Reel/Frame 075416/0660 →
PATENT SECURITY AGREEMENT (1L) Recorded Apr 6, 2026
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075416/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2026
From: OPSIDIO, LLC
To: INSMED INCORPORATED
Reel/Frame 073451/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2020
From: PHILLIPS, MARTIN
To: OPSIDIO, LLC
Reel/Frame 054426/0585 →
Continuity (2)
Provisional Application 62900927 · Sep 16, 2019
Related Publication 20210079084A1 · Mar 18, 2021
Cited By (1)
US 12,410,246